GENELUX CORPORATION

The global cancer gene therapy market is projected to grow from $2.3B in 2023 to $8.8B by 2030, driven by advances in gene editing, personalized medicine, and rising cancer incidence. Key technologies like CRISPR and next-generation sequencing are shaping the market, while challenges include high costs and regulatory hurdles.

Genelux Corp. announced Q3 2024 financial results, initiating a Phase 2 lung cancer trial (VIRO-25) and ongoing Phase 1b/2 SCLC trial in China. Both trials use Olvi-Vec, showing positive outcomes in lung cancer and reversing platinum resistance. CEO Thomas Zindrick anticipates interim SCLC data by end of 2024, with Phase 3 PRROC and Phase 2 NSCLC data in 2025. Financial highlights include $35.1 million in cash and investments, R&D expenses of $4.1 million, G&A expenses of $2.9 million, and a net loss of $6.5 million.

Genelux Corporation initiated Phase 2 VIRO-25 trial evaluating systemically delivered Olvi-Vec in recurrent NSCLC patients who failed frontline platinum and ICI therapies. The trial aims to assess efficacy and safety of Olvi-Vec combined with platinum-doublet chemotherapy + ICI versus docetaxel. Interim data expected mid-2025.